Dr. Yuanjie Mao has led a report published in JAMA Oncology considering the correlation between daily insulin dose and cancer incidence (the amount of new cases) among patients with type 1 diabetes, discovering that higher insulin dose is positively connected with cancer incidence and that the association is stronger the type of with insulin resistance.
“In patients with type 1 diabetes, our results show that traditional metabolic factors such as for example obesity (represented by body mass index), sugar control (represented by Hemoglobin A1c), and blood circulation pressure control usually do not keep company with cancer incidence,” Mao said. “However, cancer incidence was higher for individuals who took larger dose of insulin. Our results implied that clinicians may need to balance the potential cancer risk when treating patients with type 1 diabetes on a higher daily insulin dose or that improving insulin sensitivity could be preferred than increasing the insulin dose.”
To conduct the analysis, Mao collaborated with Wenjun Zhong, Ph.D., an epidemiologist of Merck Research Labs in West Point, Pa. to investigate the associations greater than 50 common risk factors such as for example smoking, alcohol use, exercise, metabolic risk factors, medication use and genealogy with cancer incidence in 1,303 patients with type 1 diabetes whose data were collected over 28 years. They acquired data from The Diabetes Control and Complications Trial (DCCT) and its own follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, from the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository and performed statistical analysis in it. DCCT was a controlled clinical trial originating with 1,441 patients with type 1 diabetes who have been randomized into conventional diabetes therapy or intensive therapy to assess whether reducing hyperglycemia would reduce the threat of complications of type 1 diabetes.
Mao also discovered that age and sex are connected with cancer incidence when evaluated separately and a daily insulin dose posed an increased threat of cancer than age, especially an increased insulin dose.
Based on the paper, once the daily insulin dose is classified into three groups, low: significantly less than 0.5; medium: higher than or add up to 0.5 or less than 0.8; and high: higher than or add up to 0.8 units/kg each day, the hazard ratios were significantly higher in the high dose versus the reduced dose group. Cancer incidence was 2.11, 2.87, and 2.91 per 1,000 persons in the reduced, medium, and high insulin dose groups, respectively.
He continued to describe that specifically, women carry an increased risk than men; however, it had been unclear what risk factors may donate to the bigger cancer incidence in type 1 diabetes.
“We realize that folks with type 1 diabetes have an increased incidence of cancer in comparison to people without diabetes,” Liz Beverly, Ph.D. co-director of the diabetes institute and professor in the Heritage College, said. “Dr. Mao’s research identifies a potential mechanism to describe this association. His findings will result in continued research of this type and potential policy changes in cancer screening and insulin dosing recommendations.”
Although previous studies have figured patients with diabetes have an increased threat of cancer generally, this is actually the first study to explore the associated cancer incidence factors in type 1 diabetes.
“Type 1 diabetes makes up about around five to 10 percent of most diabetes cases, and recent studies in type 1 diabetes also found an increased incidence of certain cancers such as for example stomach, liver, pancreas, endometrium and kidney cancers in the populace compared with the overall population,” Mao explained. “Whereas, in type 2 diabetes, increased risk is related to metabolic factors such as for example obesity, chronic inflammation status, and insulin resistance.”
Even though results of the analysis suggest that the bigger the dose of insulin, the bigger the cancer incidence, Mao says further investigation continues to be necessary.
Mao graduated from Peking University having an M.D. and Ph.D. and had residency training in internal medicine at the Cleveland Clinic Akron General and fellow trained in Endocrinology, Diabetes, and Metabolism at the University of Arkansas. Since that time, he’s got been working at Ohio University being an assistant clinical professor in the Department of Specialty Medicine and the Diabetes Institute. He could be also dealing with OhioHealth being an endocrinologist in the Castrop Center and at O’Bleness Hospital. His specialization is in diabetes, thyroid diseases, osteoporosis, along with other endocrine disorders. As well as the current study, he could be also focusing on other clinical trials on obesity, type 1 diabetes, and type 2 diabetes.
More info: Wenjun Zhong et al, Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes, JAMA Oncology (2022). DOI: 10.1001/jamaoncol.2022.2960
Citation: Study finds association between high insulin dosage and cancer (2022, July 29) retrieved 29 July 2022 from https://medicalxpress.com/news/2022-07-association-high-insulin-dosage-cancer.html
This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.